Public health & disease milestones | Good News for Humankind

Filling vaccine syringe, for article on HPV vaccine

England records zero cervical cancer deaths in young women, crediting HPV vaccine

By Peter Schulte / June 18, 2026 / Good News For Humankind

HPV vaccination is proving it can do something remarkable: wipe out a cancer entirely in a generation. England’s school-based program, now nearly two decades old, has driven cervical cancer deaths to zero among women in their early twenties — a cohort where dozens of deaths would otherwise have been expected. Researchers say this is only the beginning, with far greater impact ahead as vaccinated generations age. It’s a powerful reminder that a single vaccine, delivered early enough, can make a whole category of suffering disappear — and that other countries have a clear, proven path to follow.

Person giving blood, for article on blood donation ban

Canada removes ban on blood donations from gay men

By Peter Schulte / June 16, 2026 / Good News For Humankind

Canada’s shift to behaviour-based blood donation screening closes a 30-year chapter in which gay and bisexual men were turned away not because of anything they did, but because of who they are. Starting September 30, 2022, donors will be assessed on individual risk behaviours — the same standard applied to everyone else. More than eight countries, including the U.K., France, and Brazil, have already made similar moves, signalling a global reckoning with policies that lagged far behind the science. This is what it looks like when health systems finally catch up to both the evidence and human dignity.

Stethoscope on top of a stock of hundred dollar bills, for article on medical debt cancellation, for article on medical debt cancellation, for article on medical debt cancellation

Connecticut has erased $513 million in medical debt for 250,000 residents since 2024

By Peter Schulte / June 9, 2026 / Good News For Humankind

Medical debt relief is reaching Connecticut residents automatically — no application, no paperwork, just a letter confirming the debt is gone. The state partnered with a nonprofit that purchases debt portfolios at steep discounts, meaning every $6.5 million in public funding has erased roughly $100 in debt for every dollar spent. Relief flows automatically to residents earning under 400% of the federal poverty level, or whose medical debt exceeds 5% of their annual income. Because medical debt falls hardest on people already facing barriers to care, this model — now spreading across multiple states — points toward something genuinely replicable.

Someone holding a Chilean flag, for article on leprosy elimination

Chile becomes the first country in the Americas to eliminate leprosy, WHO verifies

By Peter Schulte / June 3, 2026 / Good News For Humankind

After more than three decades without a locally acquired case, Chile has become just the second country in the world — after Jordan — to be officially verified by the World Health Organization as having eliminated leprosy.
The verification, announced jointly by WHO and the Pan American Health Organization, marks the end of a long arc. Chile’s last locally acquired case was reported in 1993, originating on Rapa Nui (Easter Island), where the disease first arrived in the late 19th century. The win came from decades of patient work: ongoing surveillance, free multidrug treatment provided through PAHO since 1995, trained clinicians, and care that prioritized dignity alongside diagnosis.
Globally, leprosy still affects more than 200,000 people a year, mostly in tropical regions, and WHO has urged Chile to keep its surveillance sharp in case the disease ever returns. But for now, an ancient illness has been pushed to the margins of one country’s medical history — and a model has been built for others to follow.

New York City park, for article on urban forest plan

New York City’s first urban forest plan targets its hottest, least-shaded blocks

By Peter Schulte / May 28, 2026 / Good News For Humankind

New York City’s first Urban Forest Plan aims to grow tree canopy from 23.4% to 30% of the city’s surface by 2040, with a focus on neighborhoods that have been left in the sun for too long. Right now, environmental justice communities sit under about 19% canopy cover, while wealthier areas enjoy 26% — a gap you can feel on a hot summer afternoon. The plan protects existing trees, expands planting on streets and private land, and trains residents, including NYCHA tenants, to care for the urban forest. It’s a hopeful reminder that shade, cooler air, and cleaner streets are infrastructure every neighborhood deserves.

Depiction of DNA, for article on gene therapy for inherited deafness

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

By Peter Schulte / May 28, 2026 / Good News For Humankind

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families.
In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within six months, and five regained normal hearing, including the ability to hear whispers. Instead of charging the millions per child that’s common for rare-disease therapies, Regeneron chose a different path. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag. Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Finger prick insulin injection, for article on once-weekly insulin

Once-weekly insulin wins U.S. approval, cutting 365 injections a year to 52

By Peter Schulte / May 27, 2026 / Good News For Humankind

Once-weekly insulin just became reality in the U.S., dropping the routine for many adults with type 2 diabetes from 365 shots a year to about 52. The FDA approved Awiqli after four phase 3 trials, covering 2,680 adults, found it matched or outperformed daily basal insulin in lowering blood glucose. For people already taking a weekly GLP-1 medication, pairing the two could mean far fewer injection days and one less thing to remember. Doctors are urging thoughtful, individualized use, especially around hypoglycemia risk and affordability. Still, with more than 500 million adults living with diabetes worldwide, treatments that make daily life easier are a quietly powerful step forward for global health.

Cancer patient reading a book, for article on pre-surgery immunotherapy

Bowel cancer patients see zero relapses three years after new immunotherapy

By Peter Schulte / May 20, 2026 / Good News For Humankind

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the immune system, sparing them months of post-surgery chemo. One participant described the cancer “melting away” before his operation. If larger trials confirm the approach, it could reshape how a meaningful slice of bowel cancer cases are treated worldwide.

Tunisian flag, for article on trachoma elimination

Tunisia eliminates trachoma as a public health problem

By Peter Schulte / May 19, 2026 / Good News For Humankind

Trachoma is officially gone as a public health problem in Tunisia — a disease that once affected at least half the country’s population. The World Health Organization has now validated Tunisia as the 31st country to eliminate it, and the first neglected tropical disease ever crossed off the country’s list. The win came from decades of patient work: nationwide screening, eye care woven into schools and clinics, hygiene outreach, and steady improvements in water and sanitation. Around the world, roughly 1.9 million people still live with trachoma-related blindness or visual impairment, and 136 million remain at risk. Tunisia’s story is proof that preventable blindness doesn’t have to stay that way — and a hopeful nudge toward the WHO’s 2030 goal of ending trachoma everywhere.

Infant feet, for article on nirsevimab RSV infant hospitalizations

Spanish study links RSV antibody to 86% drop in infant hospitalizations

By Peter Schulte / May 14, 2026 / Good News For Humankind

Nirsevimab, a long-acting antibody given to every infant in one Spanish region, cut RSV hospitalizations by 86% compared to previous seasons, according to a new study out of Valladolid University. Babies under six months — the group hit hardest by RSV every winter — saw the biggest drop, with pediatric intensive care admissions falling sharply too. Unlike a traditional vaccine, the shot delivers ready-made antibodies directly, which matters for newborns whose immune systems are still developing. Several European countries and the U.S. have already added it to routine infant care, and early data abroad echo the Spanish results. The remaining challenge is making sure families in lower-income countries, where RSV hits hardest, aren’t left waiting.